Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy

ArticleinBiology of Blood and Marrow Transplantation 18(2):S247-S247 · February 2012with40 Reads
Impact Factor: 3.40 · DOI: 10.1016/j.bbmt.2011.12.129